Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/320256
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.identifier.isbn1744-7658pt
dc.typeResenhapt_BR
dc.titleDrugs In Early Clinical Development For Systemic Lupus Erythematosuspt_BR
dc.contributor.authorPostalpt_BR
dc.contributor.authorM; Sinicatopt_BR
dc.contributor.authorNA; Appenzellerpt_BR
dc.contributor.authorS; Niewoldpt_BR
dc.contributor.authorTBpt_BR
unicamp.author.emailniewold.timothy@mayo.edupt_BR
dc.subjectSystemic Lupus Erythematosuspt_BR
dc.subjectCytokinept_BR
dc.subjectT Cellpt_BR
dc.subjectB Cellpt_BR
dc.description.abstractWhile immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.en
dc.relation.ispartofExpert Opinion on Investigational Drugspt_BR
dc.publisher.cityABINGDONpt_BR
dc.publisherTAYLOR & FRANCIS LTDpt_BR
dc.date.issued2016pt_BR
dc.identifier.citationExpert Opinion On Investigational Drugs. TAYLOR & FRANCIS LTD, n. 25, n. 5, p. 573 - 583.pt_BR
dc.language.isoEnglishpt_BR
dc.description.volume25pt_BR
dc.description.issuenumberpt_BR
dc.description.firstpage573pt_BR
dc.description.lastpage583pt_BR
dc.rightsfechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1354-3784pt_BR
dc.identifier.wosidWOS:000374778200007pt_BR
dc.identifier.doi10.1517/13543784.2016.1162291pt_BR
dc.identifier.urlhttp://www.tandfonline.com/doi/abs/10.1517/13543784.2016.1162291?journalCode=ieid20pt_BR
dc.description.sponsorshipFundacao Apoio A Pesquisa Estado Sao Paulo-Brasil [FAPESP 2008/02917-0, 2009/06049-6, 2009/15286-1]pt_BR
dc.description.sponsorshipConselho Nacional Pesquisa Desenvolvimento-Brasil (CNPq) [300447/2009-4, 471343/2011-0, 302205/2012-8, 473328/2013-5, 304255/2015-7]pt_BR
dc.description.sponsorshipNational Institutes of Health [AR060861, AR057781, AR065964, AI071651]pt_BR
dc.description.sponsorshipRheumatology Research Foundationpt_BR
dc.description.sponsorshipCureJM Foundationpt_BR
dc.description.sponsorshipMayo Clinic Foundationpt_BR
dc.description.sponsorshipLupus Foundation of Minnesotapt_BR
dc.description.sponsorshipEMD Seronopt_BR
dc.description.sponsorshipJanssen Pharmaceuticalspt_BR
dc.description.sponsorship1Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt_BR
dc.description.sponsorship1Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.date.available2016-12-06T18:31:16Z-
dc.date.accessioned2016-12-06T18:31:16Z-
dc.description.provenanceMade available in DSpace on 2016-12-06T18:31:16Z (GMT). No. of bitstreams: 0 Previous issue date: 2016en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/320256-
dc.description.conferencelocationpt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.